PITTSBURGH, Sept. 07, 2017 -- II-VI Incorporated (NASDAQ:IIVI), a leading provider of transceiver-embedded optical amplifiers, today announced the introduction of its new Flexible Structure Optical Module (FlexSOM) Erbium Doped Fiber Amplifier (EDFA) platform designed to enable ultra-compact amplification in next-generation 100, 200 and 400G coherent transceivers.
The fast growth in datacenter buildouts is rapidly increasing the bandwidth requirements on datacenter interconnects and driving the demand for coherent transceivers with higher bit rates and smaller form-factors. II-VI’s FlexSOM EDFA is a breakthrough in enabling high performance amplifiers to be custom fit to the narrow spaces within these transceiver modules.
“Our FlexSOM platform was developed in response to our customers’ demands to fit high performance EDFA within the challenging form factors of coherent transceivers,” said Dr. Sanjai Parthasarathi, Vice President, Product Marketing and Strategy, Optical Communications Group. “We are completing the qualification stage with certain customers and we are ramping up production.”
C-band configurations of the FlexSOM platform are released for production and L-band versions are available in sample quantities. The platform greatly facilitates the integration of II-VI’s portfolio of products for transceiver-embedded amplifiers, including II-VI’s leading edge 3-pin uncooled micro pumps and compact hybrid-passive components. The FlexSOM platform concept and design is covered by multiple granted and pending patents in the U.S. and China.
II-VI at ECOC 2017, Sep. 18-20, 2017, Booth #252
II-VI will showcase new products at ECOC 2017 that are driven by advances in our materials and technology platforms. The product showcase will include differentiated subsystems solutions, highly compact optical amplifier solutions tailored to enable high bit-rate DWDM transceivers, novel embedded monitoring solutions for transport networks, as well as key devices and sub-assemblies for datacenter transceivers.
About II-VI Incorporated
II-VI Incorporated, a global leader in engineered materials and optoelectronic components, is a vertically integrated manufacturing company that develops innovative products for diversified applications in the industrial, optical communications, military, life sciences, semiconductor equipment, and consumer markets. Headquartered in Saxonburg, Pennsylvania, the Company has research and development, manufacturing, sales, service, and distribution facilities worldwide. The Company produces a wide variety of application-specific photonic and electronic materials and components, and deploys them in various forms, including integrated with advanced software to enable our customers. For more information, please visit us at www.ii-vi.com.
CONTACT: Mark Lourie Dir. Corporate Communications [email protected] www.ii-vi.com


Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



